Cancure
  • Home
  • About
    • Vision
    • Board & Management
    • Scientific Advisors
  • Cancer
    • Current Treatments
    • Market
  • Therapies
    • Genvax – lead candidate CNC118
    • Galectin – lead candidate CNC225
    • Mitocans – lead candidate CNC332
    • Combination Therapy
    • Genvax vs. CAR-T
    • Development Program
    • References
  • Investors
    • Investors Snapshot
    • News
    • Public Documents
  • Contact
  • Glossary of Terms
  • Search
  • Menu Menu
Cancure

VISION

Cancure’s scientific vision is guided by Professor Stephen Ralph and Professor Jiri Neuzil, world leaders in immunology and mitochondrial biology respectively. Professors Ralph and Neuzil have published extensively, with decades of research conducted at Monash University in Melbourne and Griffith University on the Gold Coast.

Statistics indicate that 50% of all people will be diagnosed with cancer at some point in their lives, and 25% of all people will suffer an undignified and agonising death from this dreadful disease. The company’s co-founders and committed investors are personally driven to combat cancer – and they have committed their lives and significant resources to find a cure.

Cancure’s suite of breakthrough therapies has the potential to make a pivotal contribution in the fight against cancer.

  • Vision
  • Board & Management
  • Scientific Advisors

NEWS

  • NousCom receives $49M to trial off-the-shelf cancer vaccine
  • AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans
  • Incyte pays MacroGenics $150M for PD-1 inhibitor
  • Gilead buys CAR-T developer Kite Pharma for $12B

Contact

Mr Craig Miles
craig@cancure.com
+61 (0) 408 778 797
PO Box 1177, Broadbeach,
Queensland, Australia 4218

Copyright © 2021 All rights reserved.
  • Twitter
  • Dribbble
Scroll to top